Investigational Drug Information for Ulimorelin
✉ Email this page to a colleague
What is the development status for investigational drug Ulimorelin?
Ulimorelin is an investigational drug.
There have been 7 clinical trials for Ulimorelin.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2011.
The most common disease conditions in clinical trials are Gastrointestinal Diseases, Digestive System Diseases, and Liver Diseases. The leading clinical trial sponsors are Norgine, Tranzyme, Inc., and Lyric Pharmaceuticals.
Summary for Ulimorelin
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 60 |
| WIPO Patent Applications | 42 |
| Japanese Patent Applications | 26 |
| Clinical Trial Progress | Phase 3 (2011-01-01) |
| Vendors | 16 |
Recent Clinical Trials for Ulimorelin
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy, Safety, and Pharmacokinetics (PK) Study of Ulimorelin in Patients With Enteral Feeding Intolerance (EFI): The PROMOTE Trial | Lyric Pharmaceuticals | Phase 2 |
| A Study to Assess Ulimorelin in Healthy Subjects | Lyric Pharmaceuticals | Phase 1 |
| A Study to Evaluate the Safety of TZP-101 (IV Ulimorelin) Administered Post-Operatively in Patients Who Have Undergone Partial Bowel Resection | Norgine | Phase 3 |
Clinical Trial Summary for Ulimorelin
Top disease conditions for Ulimorelin
Top clinical trial sponsors for Ulimorelin
US Patents for Ulimorelin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
